Page 171 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPTEr 9 Cytokines and Cytokine Receptors 153

test of the pathogenic role of the targeted cytokine. Bringing 11. Codarri L, Gyulveszi G, Tosevski V, et al. RORgammat drives production of
cytokine blockade into the clinics has helped unravel the complex the cytokine GM-CSF in helper T cells, which is essential for the effector
web of interactions between cytokines in human autoimmune phase of autoimmune neuroinflammation. Nat Immunol 2011;12:560–7.
and inflammatory conditions. 12. Hamilton JA. GM-CSF as a target in inflammatory/autoimmune disease:
current evidence and future therapeutic potential. Expert Rev Clin
Immunol 2015;11:457–65.
ON THE HOrIZON 13. Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases:
critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9,
• Although the number of cytokines already seems vast, it is likely that 15, and 21, and their signaling pathways. Immunol Rev 2004;202:67–83.
more will be discovered in the future. 14. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2.
• As continued improvement in the imaging of cells and macromolecular Nat Rev Immunol 2004;4:665–74.
complexes improves, it is likely that we will obtain new insights into 15. Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic
how cytokines actually signal. self-tolerance and autoimmune disease. Int Rev Immunol
• Improved understanding of regulators like the suppressors of cytokine 2005;24:211–26.
signaling (SOCS) proteins should offer new therapeutic opportunities. 16. Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via
• Additional therapeutic options for the future may include the use STAT5 constrains T helper 17 cell generation. Immunity 2007;26:371–81.
synthetic cytokines and the creation of bispecific antibodies to target 17. Johnston RJ, Choi YS, Diamond JA, et al. STAT5 is a potent negative
more than one cytokine or cytokine receptor at the same time. regulator of TFH cell differentiation. J Exp Med 2012;209:243–50.
18. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in
multiple sclerosis. Lancet Neurol 2008;7:538–47.
CONCLUSIONS AND SUMMARY 19. Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling
mechanisms and biologic functions. Annu Rev Immunol 1999;17:701–38.
Cytokines encompass a wide range of molecules that are essential 20. Risma KA, Wang N, Andrews RP, et al. V75R576 IL-4 receptor alpha is
for communication between cells of the immune system and associated with allergic asthma and enhanced IL-4 receptor function. J
other nonimmune cells. Although the number of cytokines already Immunol 2002;169:1604–10.
seems vast, it is likely that more will be discovered in the future. 21. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of
Considerable progress has been made in defining the in vivo lymphokine secretion lead to different functional properties. Annu Rev
Immunol 1989;7:145–73.
functions of various cytokines. Equally impressive have been 22. Lee GR, Kim ST, Spilianakis CG, et al. T helper cell differentiation:
advances in our understanding how dysregulation of cytokines regulation by cis elements and epigenetics. Immunity 2006;24:369–79.
and cytokine signaling contribute to human disease. Cytokine 23. Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in
and anticytokine therapies are being successfully used in the adults with moderate-to-severe atopic dermatitis inadequately controlled
clinic. It is likely that their use will increase with advances in by topical treatments: a randomised, placebo-controlled, dose-ranging
the understanding of the immunobiology of these cytokines. phase 2b trial. Lancet 2016;387:40–52.
24. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in
Please check your eBook at https://expertconsult.inkling.com/ the life and death of lymphocytes: implications for immunotherapy.
for self-assessment questions. See inside cover for registration Immunity 2001;14:105–10.
details. 25. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol
2011;29:621–63.
26. Chapuis AG, Lee SM, Thompson JA, et al. Combined IL-21-primed
REFERENCES polyclonal CTL plus CTLA4 blockade controls refractory metastatic
melanoma in a patient. J Exp Med 2016;213:1133–9.
1. Dumonde DC, Wolstencroft RA, Panayi GS, et al. “Lymphokines”: 27. He H, Wisner P, Yang G, et al. Combined IL-21 and low-dose IL-2
non-antibody mediators of cellular immunity generated by lymphocyte therapy induces anti-tumor immunity and long-term curative effects in a
activation. Nature 1969;224:38–42. murine melanoma tumor model. J Transl Med 2006;4:24.
2. Thompson AT, Lotze MT. The cytokine handbook. San Diego, CA: 28. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric
Academic Press; 2003. cytokines: new players in the regulation of T cell responses. Immunity
3. Cohen S, Bigazzi PE, Yoshida T. Commentary. Similarities of T cell 2003;19:641–4.
function in cell-mediated immunity and antibody production. Cell 29. Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23
Immunol 1974;12:150–9. and the immunoregulatory roles of STAT4. Immunol Rev
4. Vilcek J. The cytokines: an overview. In: Thompson AW, Lotze M, 2004;202:139–56.
editors. The cytokine handbook. San Diego, CA: Academic Press; 2003. 30. Smale ST, Fisher AG. Chromatin structure and gene regulation in the
p. 3–18. immune system. Annu Rev Immunol 2002;20:427–62.
5. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and 31. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of
new strategies for treating autoimmune diseases. Nat Rev Rheumatol tralokinumab in patients with severe uncontrolled asthma: a randomised,
2016;12:25–36. double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med
6. Boulay JL, O’Shea JJ, Paul WE. Molecular phylogeny within type I 2015;3:692–701.
cytokines and their cognate receptors. Immunity 2003;19:159–63. 32. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in
7. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. adults with asthma. N Engl J Med 2011;365:1088–98.
Annu Rev Immunol 1997;15:797–819. 33. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine
8. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: produced by activated T cells, induces dermatitis in mice. Nat Immunol
importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2004;5:752–60.
2012;8:1237–47. 34. Perrigoue JG, Zaph C, Guild K, et al. IL-31-IL-31R interactions limit the
9. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with magnitude of Th2 cytokine-dependent immunity and inflammation
divergent functions. Nat Rev Immunol 2005;5:521–31. following intestinal helminth infection. J Immunol 2009;182:6088–94.
10. Croxford AL, Lanzinger M, Hartmann FJ, et al. The cytokine GM-CSF 35. Watanabe N, Hanabuchi S, Soumelis V, et al. Human thymic stromal
Drives the inflammatory signature of CCR2+ Monocytes and licenses lymphopoietin promotes dendritic cell-mediated CD4+ T cell
autoimmunity. Immunity 2015;43:502–14. homeostatic expansion. Nat Immunol 2004;5:426–34.